Literature DB >> 24803808

Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire.

Dennis Yang1, Shauna L Hillman1, Ann M Harris1, Pamela S Sinicrope1, Mary E Devens1, David A Ahlquist1.   

Abstract

AIM: To explore patient interest in a potential multi-organ stool-DNA test (MUST) for pan-digestive cancer screening.
METHODS: A questionnaire was designed and mailed to 1200 randomly-selected patients from the Mayo Clinic registry. The 29-item survey questionnaire included items related to demographics, knowledge of digestive cancers, personal and family history of cancer, personal concern of cancer, colorectal cancer (CRC) screening behavior, interest in MUST, importance of test features in a cancer screening tool, and comparison of MUST with available CRC screening tests. All responses were summarized descriptively. χ(2) and Rank Sum Test were used for categorical and continuous variables, respectively.
RESULTS: Completed surveys were returned by 434 (29% aged 50-59, 37% 60-69, 34% 70-79, 52% women). Most participants (98%) responded they would use MUST. In order of importance, respondents rated multi-cancer detection, absence of bowel preparation, safety and noninvasiveness as most attractive characteristics. For CRC screening, MUST was preferred over colorectal-only stool-DNA testing (53%), occult blood testing (75%), colonoscopy (84%), sigmoidoscopy (91%), and barium enema (95%), P < 0.0001 for each. Among those not previously screened, most (96%) indicated they would use MUST if available. Respondents were confident in their ability to follow instructions to perform MUST (98%). Only 9% of respondents indicated that fear of finding cancer was a concern with MUST, and only 3% indicated unpleasantness of stool sampling as a potential barrier.
CONCLUSION: Patients are receptive to the concept of MUST, preferred MUST over conventional CRC screening modalities and valued its potential feature of multi-cancer detection.

Entities:  

Keywords:  Colorectal cancer screening; Gastrointestinal cancer screening; Patient perceptions; Stool-DNA testing

Mesh:

Substances:

Year:  2014        PMID: 24803808      PMCID: PMC4009529          DOI: 10.3748/wjg.v20.i17.4972

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  Next-generation stool DNA testing: expanding the scope.

Authors:  David A Ahlquist
Journal:  Gastroenterology       Date:  2009-04-18       Impact factor: 22.682

2.  Predictors of nonadherence to screening colonoscopy.

Authors:  Thomas D Denberg; Trisha V Melhado; John M Coombes; Brenda L Beaty; Kenneth Berman; Tim E Byers; Alfred C Marcus; John F Steiner; Dennis J Ahnen
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

3.  Patient preferences and adherence to colorectal cancer screening in an urban population.

Authors:  Randi L Wolf; Charles E Basch; Corey H Brouse; Celia Shmukler; Steven Shea
Journal:  Am J Public Health       Date:  2006-03-29       Impact factor: 9.308

Review 4.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

Authors:  Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer
Journal:  Gastroenterology       Date:  2008-02-08       Impact factor: 22.682

5.  Patterns of colorectal cancer screening uptake among men and women in the United States.

Authors:  Helen I Meissner; Nancy Breen; Carrie N Klabunde; Sally W Vernon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

6.  Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects.

Authors:  Robert A Smith; Vilma Cokkinides; Harmon J Eyre
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

7.  Measuring patient preferences for colorectal cancer screening using a choice-format survey.

Authors:  Deborah A Marshall; F Reed Johnson; Kathryn A Phillips; John K Marshall; Lehana Thabane; Nathalie A Kulin
Journal:  Value Health       Date:  2007 Sep-Oct       Impact factor: 5.725

8.  Patient preferences for colorectal cancer screening: how does stool DNA testing fare?

Authors:  Paul C Schroy; Subodh Lal; Julie T Glick; Patricia A Robinson; Philippe Zamor; Timothy C Heeren
Journal:  Am J Manag Care       Date:  2007-07       Impact factor: 2.229

9.  Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients.

Authors:  Sarah T Hawley; Robert J Volk; Partha Krishnamurthy; Maria Jibaja-Weiss; Sally W Vernon; Suzanne Kneuper
Journal:  Med Care       Date:  2008-09       Impact factor: 2.983

10.  Barriers to colorectal cancer screening in community health centers: a qualitative study.

Authors:  Karen E Lasser; John Z Ayanian; Robert H Fletcher; Mary-Jo DelVecchio Good
Journal:  BMC Fam Pract       Date:  2008-02-27       Impact factor: 2.497

View more
  4 in total

Review 1.  Stool DNA methylation assays in colorectal cancer screening.

Authors:  Tanya Kadiyska; Alexander Nossikoff
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

2.  DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA.

Authors:  Hadi Babaei; Mohsen Mohammadi; Rasoul Salehi
Journal:  Niger Med J       Date:  2016 Jul-Aug

3.  Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening.

Authors:  Cuiping Yang; Wei Wu; Yanping Yang; Xiaojin Yang; Jing Sun; Weiyu Zhang; Kun Liu; Haifeng Ying; Songyao Jiang; Xiaojun Yu; Yiqing Shi; Yufen Zhou; Shiyan Zhu; Ying Xu; Yanfei Ding; Ling Xie; Boer Cai; Xiaorong Xin; Ping Chen; Ren Zhao; Yunlin Wu
Journal:  Oncol Lett       Date:  2020-05-25       Impact factor: 2.967

4.  Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults.

Authors:  Emily Weiser; Philip D Parks; Rebecca K Swartz; Jack Van Thomme; Philip T Lavin; Paul Limburg; Barry M Berger
Journal:  J Med Screen       Date:  2020-02-13       Impact factor: 2.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.